Abstract
A 47-year-old female patient with Behçet's disease had been treated with colchicine, prednisolone, cyclosporine A, and infliximab. Because she relapsed, however, treatment with tocilizumab, a humanized anti-interleukin 6 receptor antibody, was started. This treatment suppressed the patient's clinical manifestations, including ocular attacks, for 1 year and improved her visual acuity. This experience indicates that tocilizumab may constitute a therapeutic option for refractory Behçet's disease.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Behcet Syndrome / drug therapy*
-
Behcet Syndrome / pathology
-
Colchicine / therapeutic use
-
Cyclosporine / therapeutic use
-
Drug Therapy, Combination
-
Female
-
Follow-Up Studies
-
Humans
-
Immunologic Factors / therapeutic use*
-
Infliximab
-
Middle Aged
-
Prednisolone / therapeutic use
-
Receptors, Interleukin-6 / immunology*
-
Remission Induction
-
Treatment Failure
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Immunologic Factors
-
Receptors, Interleukin-6
-
Cyclosporine
-
Prednisolone
-
Infliximab
-
tocilizumab
-
Colchicine